felin
coronavirus
fcov
belong
genu
alphacoronaviru
subfamili
coronavirina
lead
pathogen
felida
around
world
horzinek
osterhau
fcov
two
antigen
distinct
serotyp
type
type
ii
balint
farsang
szeredi
et
al
serotyp
occur
two
pathotyp
felin
enter
coronaviru
fecv
felin
infecti
periton
viru
fipv
fecv
mainli
replic
lower
portion
intestin
tract
spread
rout
present
clinic
mild
inappar
enter
pedersen
et
al
herrewegh
et
al
balint
farsang
zadori
et
al
hand
fipv
effici
replic
macrophagesmonocyt
lead
felin
infecti
periton
fip
highli
lethal
system
granulomat
diseas
wild
domest
cat
addi
et
al
pedersen
balint
farsang
szeredi
et
al
balint
farsang
zadori
et
al
kipar
meli
fip
immunemedi
diseas
featur
antibodydepend
enhanc
ade
phenomenon
weiss
scott
vennema
et
al
tirado
yoon
virusspecif
antibodi
induc
upon
infect
fipv
cat
protect
enhanc
infect
fipv
thu
acceler
diseas
symptom
weiss
scott
vennema
et
al
tirado
yoon
takano
et
al
henc
littl
progress
develop
clinic
vaccin
fipv
although
varieti
method
tri
avirul
vaccin
attenu
live
fipv
vaccin
recombin
vaccin
pedersen
like
coronavirus
fipv
contain
singlestrand
positivesens
polyadenyl
rna
genom
encod
two
larg
polyprotein
need
process
protein
genom
replic
dye
siddel
process
mediat
two
virusencod
proteinas
also
name
main
proteas
mpro
respons
cleavag
site
thu
play
pivot
role
digest
process
indispens
viral
replic
dye
siddel
critic
role
viru
replic
make
ideal
target
antifipv
drug
design
yang
et
al
anand
et
al
date
sever
crystal
structur
coronaviru
main
proteas
solv
anand
et
al
yang
et
al
hilgenfeld
base
structur
analysi
main
proteas
idea
design
widespectrum
inhibitor
cov
propos
studi
report
crystal
preliminari
crystallograph
studi
fipv
main
proteas
complex
design
michael
acceptor
inhibitor
name
supplementari
fig
code
sequenc
fipv
main
proteas
synthes
clone
vector
use
bamhi
xhoi
restrict
site
tabl
recombin
plasmid
verifi
sequenc
transform
escherichia
coli
strain
protein
express
cultur
grown
lb
medium
contain
mg
ampicillin
k
optic
densiti
nm
reach
isopropyl
ad
final
concentr
mm
cultur
induc
express
fipv
main
proteas
k
h
thereaft
centrifug
use
harvest
cell
bacteri
pellet
resuspend
pb
mm
nacl
mm
mm
kcl
mm
ph
supplement
mm
dithiothreitol
dtt
glycerol
sonic
k
bacteri
lysat
centrifug
min
k
precipit
discard
supernat
load
onto
dispos
column
contain
glutathion
sepharos
affin
resin
pharmacia
purifi
gsttag
fipv
main
proteas
fusion
protein
subject
oncolumn
cleavag
use
commerci
presciss
proteas
pharmacia
k
h
proteas
ad
final
concentr
mg
proteolysi
pb
five
addit
residu
gplg
left
nterminu
fipv
main
proteas
result
protein
interest
purifi
anionexchang
chromatographi
use
hitrap
q
column
ge
healthcar
linear
gradient
mm
nacl
mm
ph
glycerol
mm
dtt
reach
puriti
analysi
fig
purifi
protein
immedi
supplement
dmso
concentr
mg
previous
report
inhibitor
yang
et
al
dissolv
dmso
final
concentr
mm
stock
ad
purifi
protein
give
molar
ratio
mix
h
protein
complex
centrifug
min
exchang
buffer
consist
mm
hepe
ph
mm
nacl
mm
dtt
use
thermo
icon
concentr
final
protein
concentr
mg
crystal
initi
stage
commerci
screen
kit
includ
crystal
screen
crystal
screen
pegion
index
hampton
research
laguna
niguel
california
usa
use
screen
preliminari
crystal
condit
fipv
main
proteas
inhibitor
crystal
trial
set
crystal
plate
k
use
hangingdrop
vapourdiffus
method
crystal
drop
care
set
mix
protein
solut
reservoir
solut
left
equilibr
reservoir
solut
initi
crystal
fipv
main
proteas
complex
inhibitor
obtain
h
condit
crystal
screen
consist
zinc
acet
dihydr
sodium
cacodyl
trihydr
ph
wv
polyethylen
glycol
optim
condit
consist
zinc
acet
dihydr
sodium
cacodyl
trihydr
ph
wv
polyethylen
glycol
fig
b
crystal
inform
summar
tabl
crystal
cryoprotect
solut
consist
zinc
acet
dihydr
sodium
cacodyl
trihydr
ph
wv
polyethylen
glycol
glycerol
mount
nylon
loop
flashcool
nitrogen
stream
k
data
collect
use
adsc
detector
beamlin
shanghai
synchrotron
radiat
facil
ssrf
wavelength
complet
data
set
collect
singl
crystal
diffract
resolut
fig
intens
data
index
integr
scale
packag
otwinowski
minor
relat
datacollect
process
statist
summar
tabl
fip
mainli
caus
fipv
lethal
system
granulomat
diseas
cat
around
world
addi
et
al
pedersen
balint
farsang
szeredi
et
al
balint
farsang
zadori
et
al
kipar
meli
howev
upon
viru
infect
induc
antibodi
enhanc
infect
instead
neutral
viru
socal
antibodydepend
enhanc
weiss
scott
vennema
et
al
tirado
yoon
thu
clinic
vaccin
fipv
success
develop
date
reason
fipv
main
proteas
indispens
viru
replic
altern
target
antivir
therapi
subject
crystallograph
studi
fipv
main
proteas
express
gsttag
protein
digest
use
commerci
presciss
proteas
pharmacia
purifi
use
anionexchang
chromatographi
hitrap
q
column
final
protein
use
crystal
trial
reach
greater
puriti
monitor
crystal
could
obtain
condit
crystal
screen
optim
crystal
diffract
highest
resolut
use
zinc
acet
dihydr
sodium
cacodyl
trihydr
ph
wv
polyethylen
glycol
glycerol
cryoprotect
crystal
belong
space
group
unitcel
paramet
b
c
base
molecular
weight
monom
matthew
coeffici
matthew
calcul
solvent
content
assum
presenc
one
molecul
per
asymmetr
unit
structur
biochem
analysi
fipv
main
proteas
complex
michael
acceptor
lead
better
design
optim
antivir
fip
